AHIP Requests National Policy That Restricts Coverage Of Aduhelm

Health insurers on June 30 requested a national Medicare coverage policy for Aduhelm that restricts coverage of the Alzheimer’s drug. CMS can initiate national coverage determinations on its own, but the AHIP petition might speed the process somewhat. On Thursday (July 8), Biogen narrowed the label for Aduhelm to indicate the drug is meant for patients with mild Alzheimer’s. The AHIP petition for a national coverage determination targets a patient population that is similar to that on the revised label...